iX Biopharma inks agreement to distribute erectile dysfunction drug in China

Singapore

PHARMACEUTICAL company iX Biopharma, through its wholly-owned subsidiary, has struck an agreement with China Resources Pharmaceutical Commercial Group Co (CRPCG) for the licensing, supply and distribution of Wafesil, a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China.

In a bourse filing on Thursday, the company said that the new licensing agreement runs for an initial term of 10 years and will "allow both parties to tap on their collective strengths and capabilities to capture the vast opportunities in the China market".